GMAB Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 39.24% compared to Genmab A/S's net margin of 21.47%. Genmab A/S's return on equity of 28.3% beat Johnson & Johnson's return on equity of 33.27%.

Genmab A/S has a consensus price target of $37.81, signalling upside risk potential of 13.15%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 0.8%. Given that Genmab A/S has higher upside potential than Johnson & Johnson, analysts believe Genmab A/S is more attractive than Johnson & Johnson.

Genmab A/S has a beta of 0.902, which suggesting that the stock is 9.809% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Genmab A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.48% to investors and pays a quarterly dividend of $1.30 per share. Genmab A/S pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genmab A/S quarterly revenues are $1B, which are smaller than Johnson & Johnson quarterly revenues of $24B. Genmab A/S's net income of $399.2M is lower than Johnson & Johnson's net income of $5.2B. Notably, Genmab A/S's price-to-earnings ratio is 14.19x while Johnson & Johnson's PE ratio is 20.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab A/S is 5.85x versus 5.46x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of 39.24% compared to Genmab A/S's net margin of 81.15%. Genmab A/S's return on equity of 28.3% beat Krystal Biotech, Inc.'s return on equity of 19.91%.

Genmab A/S has a consensus price target of $37.81, signalling upside risk potential of 13.15%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $229.00 which suggests that it could fall by -9.19%. Given that Genmab A/S has higher upside potential than Krystal Biotech, Inc., analysts believe Genmab A/S is more attractive than Krystal Biotech, Inc..

Genmab A/S has a beta of 0.902, which suggesting that the stock is 9.809% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.528%.

Genmab A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab A/S pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Genmab A/S quarterly revenues are $1B, which are larger than Krystal Biotech, Inc. quarterly revenues of $97.8M. Genmab A/S's net income of $399.2M is higher than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Genmab A/S's price-to-earnings ratio is 14.19x while Krystal Biotech, Inc.'s PE ratio is 37.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab A/S is 5.85x versus 20.16x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merus NV has a net margin of 39.24% compared to Genmab A/S's net margin of -786.17%. Genmab A/S's return on equity of 28.3% beat Merus NV's return on equity of -53.47%.

Genmab A/S has a consensus price target of $37.81, signalling upside risk potential of 13.15%. On the other hand Merus NV has an analysts' consensus of $97.00 which suggests that it could grow by 0.08%. Given that Genmab A/S has higher upside potential than Merus NV, analysts believe Genmab A/S is more attractive than Merus NV.

Genmab A/S has a beta of 0.902, which suggesting that the stock is 9.809% less volatile than S&P 500. In comparison Merus NV has a beta of 1.061, suggesting its more volatile than the S&P 500 by 6.069%.

Genmab A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab A/S pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.

Genmab A/S quarterly revenues are $1B, which are larger than Merus NV quarterly revenues of $12.2M. Genmab A/S's net income of $399.2M is higher than Merus NV's net income of -$95.5M. Notably, Genmab A/S's price-to-earnings ratio is 14.19x while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab A/S is 5.85x versus 121.83x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk A/S has a net margin of 39.24% compared to Genmab A/S's net margin of 26.68%. Genmab A/S's return on equity of 28.3% beat Novo Nordisk A/S's return on equity of 68.76%.

Genmab A/S has a consensus price target of $37.81, signalling upside risk potential of 13.15%. On the other hand Novo Nordisk A/S has an analysts' consensus of $53.33 which suggests that it could grow by 2.13%. Given that Genmab A/S has higher upside potential than Novo Nordisk A/S, analysts believe Genmab A/S is more attractive than Novo Nordisk A/S.

Genmab A/S has a beta of 0.902, which suggesting that the stock is 9.809% less volatile than S&P 500. In comparison Novo Nordisk A/S has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.994%.

Genmab A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk A/S offers a yield of 3.3% to investors and pays a quarterly dividend of $0.58 per share. Genmab A/S pays -- of its earnings as a dividend. Novo Nordisk A/S pays out 35.93% of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genmab A/S quarterly revenues are $1B, which are smaller than Novo Nordisk A/S quarterly revenues of $11.7B. Genmab A/S's net income of $399.2M is lower than Novo Nordisk A/S's net income of $3.1B. Notably, Genmab A/S's price-to-earnings ratio is 14.19x while Novo Nordisk A/S's PE ratio is 15.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab A/S is 5.85x versus 5.00x for Novo Nordisk A/S. Usually stocks with elevated PS ratios are considered overvalued.